< 1 minute read
Dec. 16, 2021

KZR-616: a Covalent Immunoproteasome Inhibitor

KZR-616

covalent immunoproteasome inhibitor subcutaneous agent in Ph. I/II for SLE and LN designed from proteasome inhibitors Drug Metabolism and Disposition Kezar Life Sciences, San Francisco, US

twitterlinkedinprintemail